Global cancer statistics

CA Cancer Journal for Clinicians

Volumn 61, Issue 2, 2011, Pages 69-90

  Jemal, Ahmedin ^a   Bray, Freddie ^b   Center, Melissa M ^a   Ferlay, Jacques ^b   Ward, Elizabeth ^a   Forman, David ^b  

^a AMERICAN CANCER SOCIETY   (United States)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CONTROL; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER STATISTICS; CANCER SURVIVAL; COLORECTAL CANCER; DEVELOPING COUNTRY; ESOPHAGUS CANCER; GEOGRAPHIC DISTRIBUTION; HUMAN; KAPOSI SARCOMA; LIP CANCER; LIVER CANCER; LUNG CANCER; MOUTH CANCER; NASOPHARYNX CANCER; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK FACTOR; RISK MANAGEMENT; STOMACH CANCER; UTERINE CERVIX CANCER; VACCINATION; INTERNATIONAL COOPERATION; NEOPLASM;

HUMANS; INTERNATIONALITY; NEOPLASMS;

EID: 79952232216     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.20107     Document Type: Article

References (168)

1. World Health Organization, The Global Burden of Disease: 2004 Update. Geneva: World Health Organization; 2008.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers CD, Parkin D. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; Year, Available at: http://globoean,iarc.fr. 2010. Last accessed 8/17/2010.
3. World Health Organization Databank, WHO Statistical Information System, Geneva: World Health Organization; Year, Available at: http://www,who,int/ whosis, 2010, Last accessed 2/16/2010.
4. Feriny J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, Int J Cancer, [published online ahead of print June 17, 2010].
5. United Nations Population Division. World Population Prospects, the 2008 Revision. New York: United Nations; Year. Available at: http://www.un.org/. 2008. Last accessed 10/30/2010.
6. Segi M. Cancer Mortality for Selected Sites in 24 Countries (1950-57). Sendai, Japan: Department of Public Health, Tohoku University of Medicine; 1960.
7. Doll R, Payne P, Waterhouse JAH, eds. Cancer Incidence in Five Continents. Vol I. Geneva: Union Internationale Contre le Cancer; 1966.
8. Sankaranarayanan R, Swaminathan R, Brenner H, et al. Cancer survival in Africa, Asia, and Central America: a populationbased study. Lancet Oncol. 2010; 11: 165-173.
9. Coleman MP, Quaresma M, Berrino F, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008; 9:730-756.
10. Jemal A, Center MM, Desantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010; 19:1893-1907.
11. Mackay J, Jemal A, Lee NC, Parkin DM. The Cancer Atlas. Atlanta, GA: American Cancer Society; 2006.
12. Hulka BS, Moorman PG. Breast cancer: hormones and other risk factors. Maturitas. 2001; 38:103-113; discussion 113-116.
13. Baan R, Straif K, Grosse Y, et al. Carcinogenicity of alcoholic beverages. Lancet Oncol. 2007; 8:292-293.
14. Key J, Hodgson S, Omar RZ, et al. Metaanalysis of studies of alcohol and breast cancer with consideration of the methodological issues. Cancer Causes Control. 2006; 17:759-770.
15. Althuis MD, Dozier JD, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 19731997. Int J Epidemiol. 2005;34:405-412. (Pubitemid 40645331)
16. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670-1674. (Pubitemid 46631679)
17. Cronin KA, Ravdin PM, Edwards BK, Sustained lower rates of breast cancer in the United States. Breast Cancer Res Treat. 2009;117:223-224.
18. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544-573.
19. Parkin DM. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer. 2009; 45:1649-1653.
20. Seradour B, Allemand H, Weill A, Ricordeau P. Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006. Bull Cancer. 2009;96:E1-E6.
21. Canfell K, Banks E, Moa AM, Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust. 2008;188:641-644.
22. Autier P, Boniol M, La Vecchia C, et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ. 2010;341:c3620.
23. Parkin DM, Nambooze S, Wabwire-Mangen F, Wabinga HR. Changing cancer incidence in Kampala, Uganda. 1991-2006. Int J Cancer. 2010;126:1187-1195.
24. Parkin DM, Whelan S, Ferlay J, Storm H, eds. Cancer Incidence in Five Continents. Vol I to VIII. Cancer Base No. 7. Lyon: IARC Press; 2005.
25. Colditz GA, Sellers TA, Trapido E. Epidemiology-identifying the causes and preventability of cancer? Nat Rev. 2006;6:75-83.
26. Ito Y, Ioka A, Tanaka M., Nakayama T, Tsukuma H. Trends in cancer incidence and mortality in Osaka, Japan: evaluation of cancer control activities. Cancer Sci. 2009;100:2390-2395.
27. Kushi LH, Byers T, Doyle C, et al. American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2006;56:254-281; quiz 313-314.
28. Anderson BO, Yip CH, Ramsey SD, et al. Breast cancer in limited-resource countries: health care systems and public policy. Breast J. 2006;12(suppl 1):S54-S69. (Pubitemid 43385273)
29. Anderson BO, Yip CH, Smith RA, et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer. 2008; 113(8 suppl):2221-2243.
30. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009;18:1688-1694.
31. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59:366-378.
32. Garcia-Alvarez A, Serra-Majem L, RibasBarba L, et al. Obesity and overweight trends in Catalonia, Spain (1992-2003): gender and socio-economic determinants. Public Health Nutr. 2007;10:1368-1378. (Pubitemid 350085192)
33. Martin JJ, Hernandez LS, Gonzalez MG, Mendez CP, Rey Galan C, Guerrero SM. Trends in childhood and adolescent obesity prevalence in Oviedo (Asturias, Spain) 1992-2006. Acta Paediatr. 2008;97:955-958. (Pubitemid 351792827)
34. de Kok IM, Wong CS, Chia KS, et al. Gender differences in the trend of colorectal cancer incidence in Singapore, 1968-2002. Int J Colorectal Dis. 2008;23:461-467.
35. Chu KC, Tarons RE, Chow WH, Hankey BF, Ries LA. Temporal patterns in colorectal cancer incidence, survival, and mortality from 1950 through 1990. J Natl Cancer Inst. 1994;86:997-1006. (Pubitemid 24209411)
36. Mitry E, Bouvier AM, Esteve J, Faivre J. Benefit of operative mortality reduction on colorectal cancer survival. Br J Surg. 2002; 89:1557-1562. (Pubitemid 35404325)
37. Sant M, Capocaccia R, Coleman MP, et al. Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer. 2001;37:1659-1667. (Pubitemid 32778613)
38. Ferrari P, Jenab M, Norat T, et al. Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer. 2007:121: 2065-2072. (Pubitemid 47463172)
39. Giovannucci E, Wu K, Cancers of the colon and rectum. In: Schottenfeld D, Fraumení JF Jr, eds. Cancer Epidemiology and Prevention. New York: Oxford University Press; 2006;809-829.
40. Boyle P. Levin B, eds; World Cancer Report 2008. Lyon, France: World Health Organization. International Agency for Research on Cancer; 2008.
41. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365-1371. (Pubitemid 23131388)
42. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:659-669.
43. Muller AD, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Intern Med. 1995;123: 904-910.
44. Lambert R, Sauvaget C, Sankaranarayanan R. Mass screening for colorectal cancer is not justified in most developing countries. Int J Cancer. 2009;125:253-256.
45. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375:1624-1633.
46. Mackay J, Eriksen M, Shafey O. The Tobacco Atlas. 2nd ed. Atlanta, GA: American Cancer Society; 2006.
47. Lam WK, White NW, Chan-Yeung MM. Lung cancer epidemiology and risk factors in Asia and Africa. Int J Tubero Lung Dis. 2004;8:1045-1057. (Pubitemid 39201249)
48. Boftetta P, Nyberg F. Contribution of environmental factors to cancer risk. Br Med Bull. 2003;68:71-94. (Pubitemid 38258221)
49. Thun MJ, Hannan LM, Adams-Campbell LL, et al, Lung cancer occurrence in neversmokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med. 2008;5: e185.
50. Spitz M, Wu X, Wilkinson A, Wei Q. Cancer of the Lung. Oxford, UK: Oxford University Press; 2006.
51. Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol. 2008;3:819-831.
52. Bray FI, Weiderpass E. Lung cancer mortality trends in 36 European countries: secular trends and birth cohort patterns by sex and region 1970-2007. Int J Cancer. 2010; 126:1454-1466.
53. Ezzati M, Henley SJ, Lopez AD, Thun MJ. Role of smoking in global and regional cancer epidemiology: current patterns and data needs. Int J Cancer. 2005;116:963-971. (Pubitemid 41209205)
54. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet. 2003;362:847-852. (Pubitemid 37130092)
55. Peto R, Lopez AD, Boreham J, Thun M. Mortality From. Smoking in Developed Countries .1950-2000. 2nd ed. Revised June 2006. Available at: http://www.ctsu.ox.ac. uk/~tobacco/SM.K-All-PAGES.pdf. International Union Against Cancer (UICC). Geneva: Switzerland. 2006. Last Accessed 7/1/2010.
56. Jemal. A, Thun MJ, Ries LA, et al, Annual report, to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst, 2008;100:1672-1694.
57. Harris JE. Cigarette smoking among successive birth cohorts of men and women in the United. States during .1900-80. J Natl Cancer Inst. 1983;71:473-479. (Pubitemid 13012122)
58. Centers for Disease Control and Prevention. Best. Practices for Comprehensive Tobacco Control Programs-2007. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2007.
59. Shafey O, Eriksen M, Ross H, Mackey J The Tobacco Atlas. 3rd ed. Atlanta, GA: American Cancer Society; 2009.
60. World Health Organization. WHO Framework Convention on Tobacco Control. Available at: http://whqlibdoc.who.int/ publications/2003/9241591013.pdf. Accessed March 9, 2010.
61. Bock CH, Schwartz AG, Ruterbusch JJ, et al. Results from a prostate cancer admixture mapping study in African-American men. Hum Genet. 2009;126:637-642.
62. Miller DC, Zheng SL, Dunn RL, et al. Germ-line mutations of the macrophage scavenger receptor .1 gene: association with prostate cancer risk in African-American men. Cancer Res. 2003;63:3486-3489. (Pubitemid 36793026)
63. Baade PD, Youlden DR, Kmjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res. 2009;53: 171.-184.
64. Kvale R, Auvinen A, Adami HO, et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst. 2007;99: 1881-1887. (Pubitemid 351767195)
65. Bray F, Lortet-Tieulent J, Feriay J, Forman D, Auvinen A, Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer. 2010:46: 3040-3052.
66. Kvale R, Moller B, Angelsen A, et al. Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway .1980-2007. Cancer Epidemiol. 2010;34:359-367.
67. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from, a randomized prostate-cancer screening trial, N Engl J Med. 2009;360:1310-1319.
68. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
69. Platz EA, Giovannucci E. Prostate cancer. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; 2006:1151-1165.
70. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int. J Cancer. 2006;118:3030-3044.
71. Bertuccio P, Chatenoud L, Levi F, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009;125:666-673.
72. Chen J, Bu XL, Wang QY, Hu PJ, Chen MH, Decreasing seroprevalence of Helicobacter pylori infection during .1993-2003 in Guangzhou, southern China. Helicobacter. 2007;12:164-169.
73. Kawakami E, Machado RS, Ogata SK, Langner M. Decrease in prevalence of Helicobacter pylori infection during a 10-year period in Brazilian children. Arq Gastroenterol. 2008;45:147-151.
74. Tkachenko MA, Zhannat NZ, Erman LV, et al. Dramatic changes in the prevalence of Helicobacter pylori infection during childhood: a 10-year follow-up study in Russia. J Pediatr Gastroenterol Nutr. 2007:45: 428-432. (Pubitemid 350307160)
75. Lee JK, Inoue M, Otani T, Iwasaki M. Sasazuki S, Tsugane S; JPHC Study Group. Gastric cancer screening and subsequent, risk, of gastric cancer: a large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer. 2006:118: 2315-2321.
76. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529-538. (Pubitemid 44307383)
77. Shin HR, Oh JK, Masuyer E, et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 2010;101:579-585.
78. London WT, McGlynn KA. Liver cancer. In: Schottenfeld D, Fraumeni FJ Jr, eds. Cancer Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; 2006:763-786.
79. Ming L, Thorgeirsson SS, Gail. MH, et al. Dominant, role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology. 2002;36:1214-1220. (Pubitemid 35253438)
80. International Agency for Research on Cancer (IARC). Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene. IARC Monographs on the Evaluation, of Carcinogenic Risks to Humans. Vol 82. Lyon, France: International Agency for Research, on Cancer; 2002.
81. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007; 37(suppl2):S88-S94.
82. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol, 2009;27:1485-1491.
83. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-20Ó4. Hepatology. 2008;48:137-145. (Pubitemid 351980469)
84. Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009:101: 1348-1355.
85. World Health Organization. Vaccine-Preventable Diseases: Monitoring System 2009 Global Summary. WHO/UNICEF Coverage Estimates for 1980-2008, as of August 2009. Available at: http://www.who. int./ immunization-monitoring/ routine/ immun.ization-covc.rage/en/index4.html. Accessed January 5, 2010.
86. Centers for Disease Control, and Prevention. (CDC). Implementation of newborn hepatitis B vaccination.....worldwide, 2006. MMWR Morb Mortal WkIy Rep. 2008;57:1249-1252.
87. Turner PC, Sylla A, Gong YY, et al. Reduction in exposure to carcinogenic anatoxins by postharvest intervention measures in west. Africa: a community-based intervention study. Lancet, 2005;365:1950-1956. (Pubitemid 40797504)
88. Parkin DM, Almonte M, Bruni L, Clifford G, Curado MP, Pineros M. Burden and trends of type-specific human papillomavirus infections and related diseases in the latin america and Caribbean region. Vaccine. 2008;26(suppl 11) :L1-L15.
89. Mathew A, George PS. Trends in incidence and mortality rates of squamous cell card-noma and adenocarcinoma of cervixworldwide. Asian Pac .1 Cancer Prev. 2009; 10:645-650.
90. Vizcaino AP, Moreno V, Bosch FX, et al. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int. J Cancer. 2000;86:429-435. (Pubitemid 30187507)
91. Sherris J, Wittet S, Kleine A, et al. Evidence-based, alternative cervical cancer screening approaches in low-resource settings. Int Perspect Sex Reprod Health. 2009;35:147-154.
92. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009:360: 1385-1394.
93. Sankaranarayanan R. HPV vaccination: the promise & problems. Indian J Med Res. 2009;130:322-326.
94. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent, human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271-278. (Pubitemid 40590263)
95. Harper DM, Franco EL, Wheeler CM, et al, Sustained efficacy up to 4.5 years of a bivalent L1. virus-like particle vaccine against human papillomavirus types 16 and .18: follow-up from a randomised control trial. Lancet. 2006;367:1247-1255.
96. Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology. 3rd edition. Geneva: World. Health Organization; 2000.
97. Gholipour C, Shalchi RA, Abbasi M. A histopathological study of esophageal cancer on the western side of the Caspian, littoral from .1994 to 2003. Dis Esophagus. 2008;21:322-327. (Pubitemid 351663448)
98. Tran GD, Sun XD, Abnet CC, et al. Prospective study of risk factors for esophageal, and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer. 2005;113:456-463. (Pubitemid 40038715)
99. Islami. F, Boffetta P, Ren JS, Pedoeim L, Khatib D, Kamangar F. High-temperature beverages and foods and esophageal cancer risk-a systematic review. Int J Cancer. 2009;125:491-524.
100. Islami. F, Pourshams A, Nasrollahzadeh D, et al. Tea drinking habits and oesophageal, cancer in a high, risk area in northern Iran: population based case-control, study. BMJ. 2009;338:b929.
101. Wu M, Liu AM, Kampman E, et al. Green tea drinking, high tea temperature and esophageal cancer in high- and low-risk, areas of. liangsu Province, China: a population-based case-control study. Int J Cancer. 2009;124:1907-1913.
102. Engel LS, Chow WH, Vaughan TL, et al, Population attributable risks of esophageal, and gastric cancers. J Natl Cancer Inst. 2003;95:1404-1413. (Pubitemid 37220460)
103. Kamangar F, Chow WH, Abnet CC, Dawsey SM. Environmental causes of esophageal cancer. Gastroenterol Clin North Am. 2009;38:27-57, vii.
104. Lee CH, Lee JM, Wu DC, et al. Independent, and combined effects of alcohol, intake, tobacco smoking and betel, quid chewing on the risk of esophageal, cancer in Taiwan. Int J Cancer. 2005;113:475-482.
105. Phukan RK, Ali MS, Chetia CK, Manama J. Betel nut and tobacco chewing; potential risk factors of cancer of oesophagus in Assam. India. Br J Cancer. 2001;85:661-667. (Pubitemid 32929461)
106. Wu IC, Lu CY, Kuo FC, et al. Interaction between cigarette, alcohol, and betel nut use on esophageal cancer risk in Taiwan. Eur J Clin Invest, 2006;36:236-241.
107. Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer. 2009;101:855-859.
108. Lepage C, Rachet B, Jooste V, Faivre J, Coleman MP. Continuing rapid increase in esophageal adenocarcinoma in England, and Wales. Am J Gastroenterol. 2008:103: 2694-2699.
109. Bosetti C, Levi F, Ferlay J, et al. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer. 2008:122: 1118-1129. (Pubitemid 351214012)
110. El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol. Hepatol, 2007;5:17-26.
111. Post PN, Siersema PD, Van Dekken H. Rising incidence of clinically evident. Barrett's oesophagus in The Netherlands: a nation-wide registry of pathology reports. Scand J Gastroenterol. 2007;42:17-22. (Pubitemid 46033041)
112. Lu CL, Lang HC, Luo JC, et al. Increasing trend of the incidence of esophageal squamous cell carcinoma, but not adenocarcinoma, in Taiwan. Cancer Causes Control. 2010;21:269-274.
113. Silverman D, Devesa S, Moore L, Rothman N. Bladder cancer. In: Schottenfeld D, Fraumeni FJ. Ir, eds. Cancer Epidemiology and Prevention. 3rd ed. Oxford: Oxford University Press; 2006:1101-1027.
114. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival, and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44:1345-1389.
115. Felix AS, Soliman AS, Khaled H, et al, The changing patterns of bladder cancer in Egypt over the past 26 years. Cancer Causes Control. 2008;19:421-429.
116. Zaghloul MS, Noun A, Moneer M, El-Baradie M, Nazmy M, Younis A. Time-trend in epidemiological and pathological, features of schistosoma- associated bladder cancer. J Egypt Natl. Cane Inst. 2008;20: 168-174.
117. Hartge P, Wang SS, Bracci PM, Devesa SS, Holly EA, Non-Hodgkin lymphoma. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer Epidemiology and Prevention. New York: Oxford University Press; 2006:898918.
118. Devesa SS, Fears T. Non-Hodgkin's lymphoma time trends: United States and international, data. Cancer Res. 1992;52(19 suppl):5432s-5440s.
119. Bahl S, Theis B, Nishri D, Marrett LD. Changing incidence of AIDS-related Kaposi sarcoma and non-Hodgkin lymphoma in Ontario, Canada. Cancer Causes Control. 2008;19:1251-1258.
120. Hartge P, Devesa SS. Quantification of the impact of known risk: factors on time trends in non-Hodgkin's lymphoma incidence. Cancer Res. 1992;52(19 suppl):5566s-5569s.
121. Eltom MA, Jemal. A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United. States from 1973 through 1998. J Natl Cancer Inst. 2002;94: 1204-1210. (Pubitemid 34993870)
122. Sriplung H, Parkin DM, Trends in the incidence of acquired immunodeficiency syn-drome-related malignancies in Thailand. Cancer. 2004;101:2660-2666. (Pubitemid 39532299)
123. Mbulaiteye SM, Katabira ET, Wabinga H, et al. Spectrum of cancers among HIVinfected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int. J Cancer. 2006;118:985-990. (Pubitemid 43157675)
124. Abdel-Fattah MM, Yassine OG. Non-Hodgkin's lymphomas in Alexandria, Egypt; incidence rates and trend study (1995-2004). Eur J Cancer Prev. 2007;16:479-485. (Pubitemid 47550010)
125. Bouvard. V, Baan R, Straif K, et al, A review of human carcinogens-Part B: biological agents. Lancet Oncol. 2009; 10: 321-322.
126. Blot WJ, McLaughlin JK, Winn DM, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988; 48:3282-3287.
127. Hashibe M, Brennan P, Chuang SC, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev. 2009;18:541-550.
128. International. Agency for Research on Cancer. Betal. Quid and Areca Nut. Chewing and Some Areca Nut Derived Nitrosamines. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 85. Lyon, France: IARC; 2004.
129. International Agency for Research on Cancer. Smokeless Tobacco and Some Tobacco-Specific N-Nitrosamines. IARC Monographs on. the Evaluation of Carcinogenic Risks to Humans. Vol 89. Lyon, France: IARC; 2007.
130. D'Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML. Oral, sexual, behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis. 2009:199: 1263-1269.
131. US Department of Health and Human Services. A Surgeon General's report on the Health Consequences of Smoking. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, Office of Smoking and Health; 2004.
132. Danaei G, Vander Hoorn S, Lopez AD, Murray C, Ezzati M; Comparative Risk Assessment collaborating group (Cancers). Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental, risk factors. Lancet. 2005; 366:1784-1793. (Pubitemid 41642642)
133. Jayalekshmi PA, Gangadharan P, Akiba S, Nair RR, Tsuji M, Rajan B. Tobacco chewing and female oral, cavity cancer risk in Karunagappally cohort, India. Br J Cancer. 2009;100:848-852.
134. Wen CP, Tsai MK, Chung WS, et al. Cancer risks from betel, quid chewing beyond oral cancer: a multiple-site carcinogen when, acting with smoking. Cancer Causes Control. 2010;21:1427-1435.
135. Ho PS, Ko YC, Yang YH, Shieh TY, Tsai CC. The incidence of oropharyngeal cancer in Taiwan: an endemic betel quid chewing area. J Oral Pathol Med. 2002;31:213-219.
136. Garavello W, Bertuccio P, Levi F, et al. The oral cancer epidemic in central, and eastern Europe. Int J Cancer. 2010;127: 160-171.
137. Mayne ST, Morse D, Winn D. Cancers of the oral cavity and pharynx. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer Epidemiology and Prevention. 3rd ed. Oxford: Oxford University Press; 2006:674-696.
138. DeLancey JO, Thun MJ, Jemal A, Ward EM. Recent trends in Black-White disparities in cancer mortality. Cancer Epidemiol Biomarkers Prev. 2008;17:2908-2912.
139. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-relat.ed and -unrelated oral squamous cell, carcinomas in the United. States. J Clin. Oncol, 2008;26:612-619. (Pubitemid 351264356)
140. Conway DI, Stockton DL, Warnakulasuriya KA, Ogden G, Maopherson LM. Incidence of oral and oropharyngeal cancer in United Kingdom (1990-1999)-recent trends and regional variation. Oral Oncol. 2006;42:586-592. (Pubitemid 43965006)
141. Hammarstedt L, Lindquist D, Dahlstrand H, et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer. 2006;119: 2620-2623. (Pubitemid 44691317)
142. Robinson KL, Macfarlane GJ. Oropharyngeal, cancer incidence and mortality in Scotland: are rates still, increasing? Oral Oncol. 2003;39:31-36. (Pubitemid 35379816)
143. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer. 2005;103:1843-1849. (Pubitemid 40563256)
144. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck, cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11:781-789,
145. Curado MP, Edwards BK, Shin HR, et al, eds. Cancer Incidence in Five Continents. Vol IX. IARC Scientific Pub. No. 160. Lyon, France: IARC; 2007.
146. Parkin DM, Whelan S, Ferlay J, Bah E, Hamdi-Cherif M. Cancer in Africa. IARC Scientific Pub. No. 153. Lyon, France: IARC Press; 2003.
147. Yu MC. Nasopharyngeal, cancer. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; 2006:620626.
148. Klein G. Nasopharyngeal carcinoma (NPC) is an enigmatic tumor. Semin Cancer Biol. 2002; 12:415-418.
149. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal, carcinoma. Cancer Epidemiol. Biomarkers Prev. 2006; 15:1765-1777.
150. Buell P. The effect of migration on the risk of nasopharyngeal cancer among Chinese. Cancer Res. 1974;34:1189-1191.
151. Henle W, Henle G. The cause of infectious mononucleosis. A. review. In: Briggs PM, De-The G, Payne LM, eds. Oncogenesis and Herpes Viruses. Lyon, France: IARC; 1972:269-274.
152. Melbye M, Ebbesen P, Levine PH, Bennike T. Early primary infection and high Epstein-Barr virus antibody titers in Greenland Eskimos at high risk for nasopharyngeal carcinoma. Int J Cancer. 1984:34: 619-623. (Pubitemid 15207001)
153. Jia WH, Huang QH, Liao J, et al. Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/ 1983-2002) in Sihui and Cangwu counties in southern China. BMC Cancer. 2006;6:178.
154. Lee AW, Foo W, Mang O, et al. Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (198099): an encouraging reduction in both incidence and mortality. Int J Cancer. 2003; 103:680-685. (Pubitemid 36091475)
155. Luo J, Chia KS, Chia SE, Reilly M, Tan CS, Ye W. Secular trends of nasopharyngeal, carcinoma incidence in Singapore, Hong Kong and Los Angeles Chinese populations. 19731997. Eur J Epidemiol. 2007;22:513-521. (Pubitemid 47222946)
156. Hsu C, Shen YC, Cheng CC, Hong RL, Chang CJ, Cheng AL. Difference in the incidence trend of nasopharyngeal and oropharyngeal carcinomas in Taiwan: implication from age-period-cohort analysis. Cancer Epidemiol Biomarkers Prev. 2006; 15:856-861. (Pubitemid 43823508)
157. Sun LM, Epplein M, Li CI, Vaughan TL, Weiss NS. Trends in the incidence rates of nasopharyngeal carcinoma among Chinese Americans living in Los Angeles County and the San Francisco metropolitan area, 1992-2002. Am J Epidemiol. 2005;162: 1174-1178. (Pubitemid 41785911)
158. Iscovich J, Boffetta P, Franceschi S, Azizi E, Sarid R. Classic kaposi sarcoma: epidemiology and risk factors. Cancer. 2000; 88: 500-517. (Pubitemid 30056922)
159. Oettle AG. Geographical, and racial differences in the frequency of Kaposi's sarcoma as evidence of environmental, or genetic causes. Acta Unio Int. Contra Cancrum, 1962;18:330-363.
160. Cook-Mozaffari P, Newton R, Beral. V, Burkitt DP. The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic. Br J Cancer. 1998;78:1521-1528. (Pubitemid 28517552)
161. Hutt MS. The epidemiology of Kaposi's sarcoma. Antibiot Chemother. 1981:29: 3-11.
162. [no authors listed]. From the Centers for Disease Control, and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition, for AIDS among adolescents and adults. JAMA. 1993;269:729-730.
163. International. Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence Qf cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000;92:1823-1830.
164. Schulz TF. KSHV (H.HV8) infection. J Infect. 2000;41:125-129.
165. Sitas F, Carrara H, Beral V, et al. Antibodies against human herpesvirus 8 in black South African patients with cancer. N Engl. J Med. 1999;340:1863-1871. (Pubitemid 29272666)
166. Chokunonga E, Levy LM, Basset!. MT, et al. Aids and cancer in Africa: the evolving epidemic in Zimbabwe. AIDS. 1999;.13: 2583-2588.
167. Wabinga HR, Parkin DM, Wabwire-Mangen F, Nambooze S. Trends in cancer incidence in Kyadondo County, Uganda, 19601997. BrJ Cancer. 2000;82:1585-1592. (Pubitemid 30204367)
168. Ferlay J, Bray F, Pisani P, Parkin DM, eds. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. CancerBase No. 5. Version 2.0. Lyon, France: IARC Press; 2004.